Table 4.

Possible considerations during COVID-19.

Newly Diagnosed MM: •Weekly velcade dosing for standard risk patients •Weekly Carfilzomib dosing regimens for young/fit patients or high-risk patients •Oral regimen; Ixazomib/Revlimid/Dex

Elderly patients: •Consider changing velcade dosing to weekly schedule •Oral regimen; Ixazomib, revlimid and dexamethasone •Consider going to monthly daratumumab earlier than recommended

Lymphopenia is unfavorable in active COVID-19 infection, hence consider lowering the dose of dexamethasone